8-K filed May 7, 2026 at 08:45 ET
Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The price reflects a 28% premium to the 30-day volume-weighted average price. Separately, Catalyst resolved all remaining FIRDAPSE patent litigation, with Hetero agreeing not to launch a generic version before January 2035, strengthening the IP outlook for the flagship product.